Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma

Liu,Jing; Wang,Yaming; Sun,Xuefei; Ji,Nan; Sun,Shengjun; Wang,Yajie; Liu,Fusheng; Cui,Qu; Wang,Chen; Liu,Yuanbo

doi:10.3892/or.2016.5308

Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma

Authors:
- Jing Liu
- Yaming Wang
- Xuefei Sun
- Nan Ji
- Shengjun Sun
- Yajie Wang
- Fusheng Liu
- Qu Cui
- Chen Wang
- Yuanbo Liu
View Affiliations

Affiliations: Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Neurosurgery, Navy General Hospital, Beijing 100050, P.R. China, Department of Neurosurgery, Institute of Neurological Sciences, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Neuroimaging Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Core Laboratory for Clinical Medical Research, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Institute of Neurological Sciences, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Internal Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: December 8, 2016 https://doi.org/10.3892/or.2016.5308
Pages: 887-894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Src homology region 2 domain-containing phosphatase-1 (SHP1) is a critical negative regulator involved in the JAK/STAT signaling pathway. The SHP1 gene has been proposed as a candidate tumor suppressor in solid and hematological malignancies and promoter methylation is an important biological process in controlling tumorigenesis. However, the detailed roles of SHP1 promoter methylation in the pathogenesis of primary central nervous system lymphoma (PCNSL) is largely unknown. In the present study, we evaluated the correlation between SHP1 expression and promoter methylation in patients with PCNSL. Thirty-three patients with PCNSL were included. We evaluated SHP1 protein expression levels by immunohistochemistry and the SHP1 promoter methylation profile by pyrosequencing analysis. For cases (n=8) with a good yield of total protein, SHP1 phosphorylation (pSHP1) and STAT3 protein expression levels were further analyzed by western blot analysis to uncover the molecular impact of SHP1 promoter methylation on downstream signaling pathways. In this study, a lower expression of SHP1 protein level was observed in 16/33 cases (48.5%) of PCNSL. SHP1 promoter methylation was predominant in 29/33 cases (87.9%) with a mean methylation level of 31.7±36.5%. The mean methylation level of the SHP1 promoter was significantly elevated in patients with a lower SHP1 protein expression, compared with those showing a higher SHP1 protein expression (50.3±38.9 vs. 14.2±24.0%, p=0.004). Further analysis showed that SHP1 protein expression was significantly decreased in patients with a higher SHP1 promoter methylation status (p=0.001), and such attenuation was correlated with a downregulation of pSHP1 (p=0.005) and an upregulation of STAT3 protein expression (p=0.020). Our data demonstrated that epigenetic alterations in the promoter region downregulated SHP1 expression in PCNSL patients. SHP1 promoter methylation was correlated with tyrosine phosphorylation and activation of transcription factor STAT3, which may contribute to the pathogenesis of PCNSL. Therapeutical regimens with epigenetic modifiers may be a potential option for patients with PCNSL.

View Figures

View References

1	Batchelor T and Loeffler JS: Primary CNS lymphoma. J Clin Oncol. 24:1281–1288. 2006. View Article : Google Scholar : PubMed/NCBI
2	Wang CC, Carnevale J and Rubenstein JL: Progress in central nervous system lymphomas. Br J Haematol. 166:311–325. 2014. View Article : Google Scholar : PubMed/NCBI
3	Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H and Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood. 117:5019–5032. 2011. View Article : Google Scholar : PubMed/NCBI
4	Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, et al: Gene expression and angiotropism in primary CNS lymphoma. Blood. 107:3716–3723. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ponzoni M, Issa S, Batchelor TT and Rubenstein JL: Beyond high-dose methotrexate and brain radiotherapy: Novel targets and agents for primary CNS lymphoma. Ann Oncol. 25:316–322. 2014. View Article : Google Scholar : PubMed/NCBI
6	Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E and Kluin PM: Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer. 35:38–48. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, et al: Pathway analysis of primary central nervous system lymphoma. Blood. 111:3200–3210. 2008. View Article : Google Scholar : PubMed/NCBI
8	Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, Schuuring E and Kluin P: Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: The importance of apoptosis and immunomodulatory pathways. J Pathol. 216:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, Suh YL, Kim SH, Kim JY, Kim SJ, et al: Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood. 117:1291–1300. 2011. View Article : Google Scholar : PubMed/NCBI
10	Deckert M, Montesinos-Rongen M, Brunn A and Siebert R: Systems biology of primary CNS lymphoma: From genetic aberrations to modeling in mice. Acta Neuropathol. 127:175–188. 2014. View Article : Google Scholar : PubMed/NCBI
11	Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, et al: M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 51:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
12	Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW and Hong YK: Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: Role of STAT6 activation as prognostic determinant. J Neurooncol. 92:65–71. 2009. View Article : Google Scholar : PubMed/NCBI
13	Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, et al: CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 121:4740–4748. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhu BM, Ishida Y, Robinson GW, Pacher-Zavisin M, Yoshimura A, Murphy PM and Hennighausen L: SOCS3 negatively regulates the gp130-STAT3 pathway in mouse skin wound healing. J Invest Dermatol. 128:1821–1829. 2008. View Article : Google Scholar : PubMed/NCBI
15	Nakata K, Suzuki Y, Inoue T, Ra C, Yakura H and Mizuno K: Deficiency of SHP1 leads to sustained and increased ERK activation in mast cells, thereby inhibiting IL-3-dependent proliferation and cell death. Mol Immunol. 48:472–480. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yi TL, Cleveland JL and Ihle JN: Protein tyrosine phosphatase containing SH2 domains: Characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 12:836–846. 1992. View Article : Google Scholar : PubMed/NCBI
17	Dixon JE: Protein tyrosine phosphatases: their roles in signal transduction. Recent Prog Horm Res. 51:405–415. 1996.PubMed/NCBI
18	Healy JI and Goodnow CC: Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol. 16:645–670. 1998. View Article : Google Scholar : PubMed/NCBI
19	Wu C, Sun M, Liu L and Zhou GW: The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
20	Chim CS, Wong AS and Kwong YL: Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol. 83:527–532. 2004. View Article : Google Scholar : PubMed/NCBI
21	Chen HE, Chang S, Trub T and Neel BG: Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol. 16:3685–3697. 1996. View Article : Google Scholar : PubMed/NCBI
22	Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH and Clark EA: CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med. 183:547–560. 1996. View Article : Google Scholar : PubMed/NCBI
23	Yi T, Zhang J, Miura O and Ihle JN: Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: Identification of potential binding sites. Blood. 85:87–95. 1995.PubMed/NCBI
24	Sugita Y, Tokunaga O, Nakashima A and Shigemori M: SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts. Pathol Int. 54:659–666. 2004. View Article : Google Scholar : PubMed/NCBI
25	Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, et al: Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62:6390–6394. 2002.PubMed/NCBI
26	Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 84:1361–1392. 1994.PubMed/NCBI
27	Patel B, Chacko G, Nair S, Anandan J, Chacko AG, Rajshekhar V and Turel M: Clinicopathological correlates of primary central nervous system lymphoma: Experience from a tertiary care center in South India. Neurol India. 63:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 101:4279–4284. 2003. View Article : Google Scholar : PubMed/NCBI
29	Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al: Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 9:R572007. View Article : Google Scholar : PubMed/NCBI
30	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
31	Kossev PM, Raghunath PN, Bagg A, Schuster S, Tomaszewski JE and Wasik MA: SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts. Am J Surg Pathol. 25:949–955. 2001. View Article : Google Scholar : PubMed/NCBI
32	Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, Hayashi K, Akagi T and Seino Y: Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 83:1849–1858. 2003. View Article : Google Scholar : PubMed/NCBI
33	Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q and Lai R: Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia. 20:1602–1609. 2006. View Article : Google Scholar : PubMed/NCBI
34	Bittorf T, Seiler J, Zhang Z, Jaster R and Brock J: SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem. 380:1201–1209. 1999. View Article : Google Scholar : PubMed/NCBI
35	Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC and Yi T: Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 16:6985–6992. 1996. View Article : Google Scholar : PubMed/NCBI
36	Kozlowski M, Mlinaric-Rascan I, Feng GS, Shen R, Pawson T and Siminovitch KA: Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med. 178:2157–2163. 1993. View Article : Google Scholar : PubMed/NCBI
37	Ma XZ, Jin T, Sakac D, Fahim S, Zhang X, Katsman Y, Bali M and Branch DR: Abnormal splicing of SHP-1 protein tyrosine phosphatase in human T cells. Implications for lymphomagenesis. Exp Hematol. 31:131–142. 2003. View Article : Google Scholar : PubMed/NCBI
38	Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, et al: Prognostic significance of O⁶-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 11:5167–5174. 2005. View Article : Google Scholar : PubMed/NCBI
39	Baeza N, Weller M, Yonekawa Y, Kleihues P and Ohgaki H: PTEN methylation and expression in glioblastomas. Acta Neuropathol. 106:479–485. 2003. View Article : Google Scholar : PubMed/NCBI
40	Cameron EE, Baylin SB and Herman JG: p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 94:2445–2451. 1999.PubMed/NCBI
41	Lenz G, Hutter G, Hiddemann W and Dreyling M: Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol. 83:628–633. 2004. View Article : Google Scholar : PubMed/NCBI
42	Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M and Korbi S: Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 19:1774–1786. 2008. View Article : Google Scholar : PubMed/NCBI
43	Khoury JD, Rassidakis GZ, Medeiros LJ, Amin HM and Lai R: Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 104:1580–1581. 2004. View Article : Google Scholar : PubMed/NCBI
44	Liu J, Sun XF, Qian J, Bai XY, Zhu H, Cui QU, Li XY, Chen YD, Wang YM and Liu YB: Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Mol Clin Oncol. 3:949–953. 2015.PubMed/NCBI
45	Tassidis H, Brokken LJ, Jirström K, Ehrnström R, Pontén F, Ulmert D, Bjartell A, Härkönen P and Wingren AG: Immuno-histochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. Int J Cancer. 126:2296–2307. 2010.PubMed/NCBI
46	Zhang L, Wang M, Wang W and Mo J: Incidence and prognostic value of multiple gene promoter methylations in gliomas. J Neurooncol. 116:349–356. 2014. View Article : Google Scholar : PubMed/NCBI